CSF1R and benign prostatic hyperplasia: Although these results support CSF1R inhibition as a promising, mechanism-based therapeutic approach for BPH, the clinical use of sunitinib should be considered with caution, carefully weighing potential adverse effects against anticipated therapeutic benefits.